Therapeutics in cognitive and behavioral neurology

Annals of Neurology

Volumn 56, Issue 1, 2004, Pages 5-7

  Small, Steven L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DEXAMPHETAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; LEVODOPA; METHYLPHENIDATE; PIRACETAM; SEROTONIN UPTAKE INHIBITOR;

ALZHEIMER DISEASE; APHASIA; ATTENTION DEFICIT DISORDER; BEHAVIOR; BRAIN REGION; COGNITION; COGNITIVE DEFECT; DRUG EFFICACY; EDITORIAL; HUMAN; LONG TERM POTENTIATION; MEMORY; MOLECULAR BIOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SHORT TERM MEMORY; SPEECH THERAPY; STROKE;

ANIMALS; BEHAVIORAL MEDICINE; CEREBROVASCULAR ACCIDENT; COGNITION DISORDERS; DOPAMINE AGENTS; HUMANS; NEUROLOGY;

EID: 3042813603     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20194     Document Type: Editorial

References (33)

1. The NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
2. Small SL. A biological model of aphasia rehabilitation: pharmacological perspectives. Aphasiology 2004;18:473-492.
3. Small SL. Pharmacotherapy of aphasia: a critical review. Stroke 1994;25:1282-1289.
4. American Heart Association. 2003 heart and stroke statistical update. Dallas, TX: American Heart Association, 2003:42.
5. Bogousslavsky J, ed. Long-term effects of stroke. Vol 54. New York: Marcel Dekker, 2002.
6. Small SL. Biological approaches to the treatment of aphasia. In: Hillis A, ed. Handbook on adult language disorders: integrating cognitive neuropsychology, neurology, and rehabilitation. Philadelphia: Psychology Press, 2001:397-411.
7. Small SL. The future of aphasia treatment. Brain Lang 2000; 71:227-232.
8. Cruice M, Worrall L, Hickson L, Murison R. Finding a focus for quality of life with aphasia: social and emotional health, and psychological well-being. Aphasiology 2003;17:333-353.
9. Gordon JK. Measuring outcomes in aphasia: bridging the gap between theory and practice ... or burning our bridges? Aphasiology 1997;11:845-854.
10. Mesulam MM, Geula C, Moran MA. Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles. Ann Neurol 1987;22:683-691.
11. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med 1992; 327:1253-1259.
12. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50: 136-145.
13. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998;158:1021-1031.
14. Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2001:CD001747.
15. Woodruff-Pak DS, Lander C, Geerts H. Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev 2002; 8:405-426.
16. Butter HJ, Lapierre Y, Firestone P, Blank A. A comparative study of the efficacy of ACTH4-9 analog, methylphenidate, and placebo on attention deficit disorder with hyperkinesis. J Clin Psychopharmacol 1983;3:226-230.
17. Armstrong CL, Hayes KM, Martin R. Neurocognitive problems in attention deficit disorder. Alternative concepts and evidence for impairment in inhibition of selective attention. Ann NY Acad Sci 2001;931:196-215.
18. Schachter HM, Pham B, King J, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. Can Med Assoc J 2001;165:1475-1488.
19. Goldstein LB. Effects of amphetamines and small related molecules on recovery after stroke in animals and man. Neuropharmacology 2000;39:852-859.
20. Goldstein LB. Amphetamines and related drugs in motor recovery after stroke. Phys Med Rehabil Clin N Am 2003;14: S125-S134.
21. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25:1099-1104.
22. Dam M, Tonin P, De Boni A, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 1996;27: 1211-1214.
23. Tanaka Y, Miyazaki M, Albert ML. Effects of increased cholinergic activity on naming in aphasia. Lancet 1997;350: 116-117.
24. Huber W, Willmes K, Poeck K, et al. Piracetam as an adjuvant to language therapy for aphasia: a randomized double-blind placebo-controlled pilot study. Arch Phys Med Rehabil 1997; 78:245-250.
25. Huber W. The role of piracetam in the treatment of acute and chronic aphasia. Pharmacopsychiatry 1999;32(suppl 1):38-43.
26. Cooper JR, Bloom FE, Roth RH. The neuropharmacological basis of neuropharmacology. 8th ed. New York: Oxford University Press, 2003.
27. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 1982;217:855-857.
28. Walker-Batson D, Smith P, Curtis S, et al. Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Stroke 1995;26:2254-2259.
29. Knecht S, Breitenstein C, Bushuven S, et al. Levodopa: Faster and better word learning in normal humans. Ann Neurol 2004; 56:20-26.
30. Gurden H, Takita M, Jay TM. Essential role of D1 but not D2 receptors in the NMDA receptor-dependent long-term potentiation at hippocampal-prefrontal cortex synapses in vivo. J Neurosci 2000;20:RC106.
31. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;67:53-83.
32. Jay TM. Dopamine: a potential substrate for synaptic plasticity and memory mechanisms. Prog Neurobiol 2003;69: 375-390.
33. Fan J, Fossella J, Sommer T, et al. Mapping the genetic variation of executive attention onto brain activity. Proc Natl Acad Sci USA 2003;100:7406-7411.